Search
Aldeyra Therapeutics Inc
ALDXAdd to Watchlist
1.295USD
-0.055-4.07%
Market hours 09/24, 11:32（ET）
78.11MMarket Cap
LossP/E TTM
About Aldeyra Therapeutics Inc Company
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Aldeyra Therapeutics Inc Profile
Ticker SymbolALDX
Company nameAldeyra Therapeutics Inc
IPO dateMay 02, 2014
CEOBrady (Todd C)
Number of employees9
Security typeOrdinary Share
Fiscal year-endMay 02
Address131 Hartwell Avenue
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421
Phone17817614904
Websitehttps://www.aldeyra.com/
Ticker SymbolALDX
IPO dateMay 02, 2014
CEOBrady (Todd C)
Company Executives of Aldeyra Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.66M
+15.05%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.66M
+15.05%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.66M
+15.05%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
195.00K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
195.00K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
195.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.66M
+15.05%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.66M
+15.05%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.66M
+15.05%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
195.00K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
195.00K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
195.00K
--
FAQs
Who are the top five shareholders of Aldeyra Therapeutics Inc?
The top five shareholders of Aldeyra Therapeutics Inc are: Dr. Todd C. Brady, M.D., Ph.D.
How many institutions hold shares of Aldeyra Therapeutics Inc (ALDX)?
As of 2026Q1, 273 institutions hold shares of Aldeyra Therapeutics Inc, with a combined market value of approximately 39.55M, accounting for 65.57% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2952347.00.